

Resource Summary Report

Generated by [RRID](#) on Aug 7, 2026

Phospho-EGF Receptor (Tyr1068) (1H12) Mouse mAb

RRID:AB_331792

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2236, RRID:AB_331792

Antibody Information

URL: http://antibodyregistry.org/AB_331792

Proper Citation: Cell Signaling Technology Cat# 2236, RRID:AB_331792

Target Antigen: Phospho-EGF Receptor (Tyr1068) (1H12) Mouse mAb

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: W, IP. Consolidation on 10/2018: AB_10077603, AB_10078790, AB_331792, AB_331793.

Antibody Name: Phospho-EGF Receptor (Tyr1068) (1H12) Mouse mAb

Description: This monoclonal targets Phospho-EGF Receptor (Tyr1068) (1H12) Mouse mAb

Target Organism: rat, h, r, human, mk

Antibody ID: AB_331792

Vendor: Cell Signaling Technology

Catalog Number: 2236

Record Creation Time: 20250820T023647+0000

Record Last Update: 20250820T140312+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-EGF Receptor (Tyr1068) (1H12) Mouse mAb.

No alerts have been found for Phospho-EGF Receptor (Tyr1068) (1H12) Mouse mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Lam D, et al. (2026) Effects of N361 Glycosylation on Epidermal Growth Factor Receptor Biological Function. *Cancers*, 18(3).

Siegel F, et al. (2026) Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. *Cancer discovery*, 16(1), 81.

Chen S, et al. (2025) LncRNA EUDAL shapes tumor cell response to hypoxia-induced constitutive EGFR activation and promotes chemoresistance in oral cancer. *International journal of oral science*, 17(1), 64.

Riley AK, et al. (2024) The deubiquitinase USP9X regulates RIT1 protein abundance and oncogenic phenotypes. *iScience*, 27(8), 110499.

Perez Verdaguer M, et al. (2022) Time-resolved proximity labeling of protein networks associated with ligand-activated EGFR. *Cell reports*, 39(11), 110950.

Franco Nitta C, et al. (2021) EGFR transactivates RON to drive oncogenic crosstalk. *eLife*, 10.

Dabelsteen S, et al. (2020) Essential Functions of Glycans in Human Epithelia Dissected by a CRISPR-Cas9-Engineered Human Organotypic Skin Model. *Developmental cell*, 54(5), 669.

Woolston A, et al. (2019) Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer. *Cancer cell*, 36(1), 35.

Choi HJ, et al. (2019) CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling. *EMBO reports*, 20(10), e48058.